This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center

This presentation reviews current treatments for early-stage and relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma. Emerging therapies, including CAR T-cell therapy, along with patient selection criteria and toxicities unique to new treatments are addressed as well.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.